Impact of Ethnicity-Specific Hepatic Microsomal Scaling Factor, Liver Weight, and Cytochrome P450 (CYP) 1A2 Content on Physiologically Based Prediction of CYP1A2-Mediated Pharmacokinetics in Young and Elderly Chinese Adults.
Journal
Clinical pharmacokinetics
ISSN: 1179-1926
Titre abrégé: Clin Pharmacokinet
Pays: Switzerland
ID NLM: 7606849
Informations de publication
Date de publication:
07 2019
07 2019
Historique:
pubmed:
16
2
2019
medline:
25
8
2020
entrez:
16
2
2019
Statut:
ppublish
Résumé
The vast majority of physiological and biological data required for physiologically based predictions are primarily available in Caucasians rather than other ethnic populations, which leads to a lack of confidence in the application of physiologically based pharmacokinetic (PBPK) modeling for ethnicity-specific prediction of pharmacokinetics in the Chinese population. In this study we recalibrate the system parameters of Chinese-specific PBPK modeling and explore for the first time the relative importance of ethnicity-specific microsomal protein per gram of liver (MPPGL), liver weight, and cytochrome P450 (CYP) 1A2 abundance to the projection of drug disposition mediated by CYP1A2 in young and elderly Chinese adults. Chinese MPPGL levels and associated variability were parameterized and incorporated for the first time into ethnicity-specific PBPK models for the Chinese adults. Parameterization of Chinese liver weights was also recalibrated on the basis of autopsy data from Chinese individuals (n = 4081) across the entire adult age range. Uncertainty surrounding the Chinese-specific CYP1A2 content has also been explored and clarified by conducting ethnicity-related PBPK simulations under different scenarios. Various ethnicity-related or 'what-if' scenarios for PBPK modeling were implemented to assess the predictive performance and explore the relative importance of ethnicity-specific MPPGL and liver weight to the projection of drug disposition mediated by CYP1A2 in terms of two typical CYP1A2 substrates, caffeine and theophylline, in young and elderly Chinese adults by comparing the predicted concentration-time data and associated pharmacokinetic parameter estimates with observations. Compared with 0.85, the liver scalar of 0.9 generally produced more accurate liver weight levels in virtual Chinese peers. Additionally, simulated MPPGL levels on the basis of Caucasian data were not able to reflect the age-independent pattern observed in Chinese adults, dissimilar to that on the basis of Chinese-specific adult MPPGL data. The modeling Scenarios A and B provided similar predictions for theophylline pharmacokinetics in young Chinese adults across different age groups, while Scenario B provided the most accurate prediction for theophylline pharmacokinetics in elderly Chinese adults. However, the use of a stratified value of CYP1A2 content derived from a Han Chinese cohort with a small sample size instead of the pooled value of all Chinese cohorts involved regardless of Chinese sub-ethnicity resulted in inadequate prediction of CYP1A2-mediated pharmacokinetics in terms of caffeine and theophylline in either young or elderly Chinese subjects. Additionally, the impact of ethnic-specific MPPGL on predictive accuracy of theophylline pharmacokinetics in elderly Chinese subjects is more evident than that of liver weight. We provided quantitative information pertaining to Chinese-specific levels of liver weight and MPPGL, and recalibrated these system parameters for PBPK modeling for young and elderly Chinese subjects. Uncertainty surrounding the Chinese-specific CYP1A2 content has also been clarified. PBPK modeling based on the recalibrated system parameters can accurately simulate CYP1A2-mediated pharmacokinetics in both young and elderly Chinese adults, particularly in elderly individuals.
Sections du résumé
BACKGROUND
The vast majority of physiological and biological data required for physiologically based predictions are primarily available in Caucasians rather than other ethnic populations, which leads to a lack of confidence in the application of physiologically based pharmacokinetic (PBPK) modeling for ethnicity-specific prediction of pharmacokinetics in the Chinese population.
OBJECTIVES
In this study we recalibrate the system parameters of Chinese-specific PBPK modeling and explore for the first time the relative importance of ethnicity-specific microsomal protein per gram of liver (MPPGL), liver weight, and cytochrome P450 (CYP) 1A2 abundance to the projection of drug disposition mediated by CYP1A2 in young and elderly Chinese adults.
METHODS
Chinese MPPGL levels and associated variability were parameterized and incorporated for the first time into ethnicity-specific PBPK models for the Chinese adults. Parameterization of Chinese liver weights was also recalibrated on the basis of autopsy data from Chinese individuals (n = 4081) across the entire adult age range. Uncertainty surrounding the Chinese-specific CYP1A2 content has also been explored and clarified by conducting ethnicity-related PBPK simulations under different scenarios. Various ethnicity-related or 'what-if' scenarios for PBPK modeling were implemented to assess the predictive performance and explore the relative importance of ethnicity-specific MPPGL and liver weight to the projection of drug disposition mediated by CYP1A2 in terms of two typical CYP1A2 substrates, caffeine and theophylline, in young and elderly Chinese adults by comparing the predicted concentration-time data and associated pharmacokinetic parameter estimates with observations.
RESULTS
Compared with 0.85, the liver scalar of 0.9 generally produced more accurate liver weight levels in virtual Chinese peers. Additionally, simulated MPPGL levels on the basis of Caucasian data were not able to reflect the age-independent pattern observed in Chinese adults, dissimilar to that on the basis of Chinese-specific adult MPPGL data. The modeling Scenarios A and B provided similar predictions for theophylline pharmacokinetics in young Chinese adults across different age groups, while Scenario B provided the most accurate prediction for theophylline pharmacokinetics in elderly Chinese adults. However, the use of a stratified value of CYP1A2 content derived from a Han Chinese cohort with a small sample size instead of the pooled value of all Chinese cohorts involved regardless of Chinese sub-ethnicity resulted in inadequate prediction of CYP1A2-mediated pharmacokinetics in terms of caffeine and theophylline in either young or elderly Chinese subjects. Additionally, the impact of ethnic-specific MPPGL on predictive accuracy of theophylline pharmacokinetics in elderly Chinese subjects is more evident than that of liver weight.
CONCLUSION
We provided quantitative information pertaining to Chinese-specific levels of liver weight and MPPGL, and recalibrated these system parameters for PBPK modeling for young and elderly Chinese subjects. Uncertainty surrounding the Chinese-specific CYP1A2 content has also been clarified. PBPK modeling based on the recalibrated system parameters can accurately simulate CYP1A2-mediated pharmacokinetics in both young and elderly Chinese adults, particularly in elderly individuals.
Identifiants
pubmed: 30767128
doi: 10.1007/s40262-019-00737-5
pii: 10.1007/s40262-019-00737-5
doi:
Substances chimiques
CYP1A2 protein, human
EC 1.14.14.1
Cytochrome P-450 CYP1A2
EC 1.14.14.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
927-941Références
Sy SK, Wang X, Derendorf H. Introduction to pharmacometrics and quantitative pharmacology with an emphasis on physiologically based pharmacokinetics. In: Schmidt S, Derendorf H, editors. Applied pharmacometrics. New York: Springer; 2014. p. 1–64.
Barrett JS, Della Casa Alberighi O, Läer S, Meibohm B. Physiologically based pharmacokinetic (PBPK) modeling in children. Clin Pharmacol Ther. 2012;92(1):40–9.
pubmed: 22669290
Li GF, Yu G, Li Y, Zheng Y, Zheng QS, Derendorf H. Quantitative estimation of plasma free drug fraction in patients with varying degrees of hepatic impairment: a methodological evaluation. J Pharm Sci. 2018;107(7):1948–56.
pubmed: 29518400
Li GF, Wang K, Chen R, Zhao HR, Yang J, Zheng QS. Simulation of the pharmacokinetics of bisoprolol in healthy adults and patients with impaired renal function using whole-body physiologically based pharmacokinetic modeling. Acta Pharmacol Sin. 2012;33(11):1359–71.
pubmed: 23085739
pmcid: 4011361
Jones HM, Chen Y, Gibson C, Heimbach T, Parrott N, Peters SA, et al. Physiologically based pharmacokinetic modeling in drug discovery and development: a pharmaceutical industry perspective. Clin Pharmacol Ther. 2015;97(3):247–62.
pubmed: 25670209
Li GF, Yu G, Liu HX, Zheng QS. Ethnic-specific in vitro-in vivo extrapolation and physiologically based pharmacokinetic approaches to predict cytochrome P450-mediated pharmacokinetics in the Chinese population: opportunities and challenges. Clin Pharmacokinet. 2014;53(2):197–202.
pubmed: 24255013
Barter ZE, Tucker GT, Rowland-Yeo K. Differences in cytochrome p450-mediated pharmacokinetics between Chinese and Caucasian populations predicted by mechanistic physiologically based pharmacokinetic modelling. Clin Pharmacokinet. 2013;52(12):1085–100.
pubmed: 23818090
Barter ZE, Chowdry JE, Harlow JR, Snawder JE, Lipscomb JC, Rostami-Hodjegan A. Covariation of human microsomal protein per gram of liver with age: absence of influence of operator and sample storage may justify interlaboratory data pooling. Drug Metab Dispos. 2008;36(12):2405–9.
pubmed: 18775982
Zhang H, Gao N, Tian X, Liu T, Fang Y, Zhou J, et al. Content and activity of human liver microsomal protein and prediction of individual hepatic clearance in vivo. Sci Rep. 2015;4(5):17671. https://doi.org/10.1038/srep17671 .
doi: 10.1038/srep17671
Shu Y, Cheng ZN, Liu ZQ, Wang LS, Zhu B, Huang SL, et al. Interindividual variations in levels and activities of cytochrome P-450 in liver microsomes of Chinese subjects. Acta Pharmacol Sin. 2001;22:283–8.
pubmed: 11742579
Shu Y, Wang LS, Xiao WM, Wang W, Huang SL, Zhou HH. Probing CYP2C19 and CYP3A4 activities in Chinese liver microsomes by quantification of 5-hydroxyomeprazole and omeprazole sulphone. Acta Pharmacol Sin. 2000;21(8):753–8.
pubmed: 11501187
Johnson TN, Tucker GT, Tanner MS, Rostami-Hodjegan A. Changes in liver volume from birth to adulthood: a meta-analysis. Liver Transplant. 2005;11:1481–93.
Barter ZE, Tucker GT, Rowland-Yeo K. Response to “Ethnicity-specific in vitro-in vivo extrapolation and physiologically based pharmacokinetic approaches to predict cytochrome P450-mediated pharmacokinetics in Chinese population: opportunities and challenges”. Clin Pharmacokinet. 2014;53(2):203.
pubmed: 24255012
Rowland Yeo K, Jamei M, Yang J, Tucker GT, Rostami-Hodjegan A. Physiologically based mechanistic modelling to predict complex drug–drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut—the effect of diltiazem on the time-course of exposure to triazolam. Eur J Pharm Sci. 2010;39(5):298–309.
pubmed: 20025966
DuBois D, DuBois E. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med. 1916;17:863.
International Atomic Energy Agency. Compilation of anatomical, physiological and metabolic characteristics for a reference Asian man. Volume 2: country reports. 1998. IAEA-TECDOC-1005. http://www-pub.iaea.org/books/IAEABooks/5301/Compilation-of-Anatomical-Physiological-and-Metabolic-Characteristics-for-a-Reference-Asian-Man-Volume-2-Country-Reports . Accessed 21 Jan 2019.
National Collaborative Group on Organ Weight Research Program. Weights of various organs in Chinese people [in Chinese]. Zhonghua Bing Li Xue Za Zhi. 1988;17(2):111–4.
Zhang HF, Wang HH, Gao N, et al. Physiological content and intrinsic activities of 10 cytochrome P450 isoforms in human normal liver microsomes. J Pharmacol Exp Ther. 2016;358(1):83–93.
pubmed: 27189963
Gao N, Tian X, Fang Y, Zhou J, Zhang H, Wen Q, et al. Gene polymorphisms and contents of cytochrome P450 s have only limited effects on metabolic activities in human liver microsomes. Eur J Pharm Sci. 2016;92:86–97.
pubmed: 27339126
Wu X, Zhao M, Pan B, Zhang J, Peng M, Wang L, et al. Complete blood count reference intervals for healthy Han Chinese adults. PLoS One. 2015;10(3):e0119669.
pubmed: 25769040
pmcid: 4358890
Qiao R, Yang S, Yao B, Wang H, Zhang J, Shang H. Complete blood count reference intervals and age- and sex-related trends of North China Han population. Clin Chem Lab Med. 2014;52(7):1025–32.
pubmed: 24497225
Miao G, Yan Y, Chuanmin Z, Naiying L. Discussion on the relationship between normal hematocrit and geographical factors in China. Clin Hemorheol Microcirc. 1997;17(6):459–65.
pubmed: 9502530
Zhou HH, Adedoyin A, Wilkinson GR. Differences in plasma binding of drugs between Caucasians and Chinese subjects. Clin Pharmacol Ther. 1990;48(1):10–7.
pubmed: 2369804
Yu G, Zhou HH, Zheng QS, Li GF. Interethnic scaling of fraction unbound of a drug in plasma and volume of distribution: an analysis of extrapolation from Caucasians to Chinese. Eur J Clin Pharmacol. 2018. https://doi.org/10.1007/s00228-018-02610-z .
Benet LZ, Broccatelli F, Oprea TI. BDDCS Applied to over 900 drugs. AAPS J. 2011;13(4):519–47.
pubmed: 21818695
pmcid: 3231854
Sun D, Lennernas H, Welage LS, Barnett JL, Landowski CP, Foster D, et al. Comparison of human duodenum and Caco-2 gene expression profiles for 12,000 gene sequences tags and correlation with permeability of 26 drugs. Pharm Res. 2002;19(10):1400–16.
pubmed: 12425456
Huang W, Lee SL, Yu LX. Mechanistic approaches to predicting oral drug absorption. AAPS J. 2009;11(2):217–24.
pubmed: 19381841
pmcid: 2691458
Rodgers T, Leahy D, Rowland M. Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. J Pharm Sci. 2005;94(6):1259–76.
pubmed: 15858854
Rodgers T, Rowland M. Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci. 2006; 95(6):1238–57 (Erratum in J Pharm Sci. 2007;96(11):3153–4).
Poulin P, Theil FP. Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. J Pharm Sci. 2002;91(1):129–56.
Berezhkovskiy LM. Volume of distribution at steady state for a linear pharmacokinetic system with peripheral elimination. J Pharm Sci. 2004;93(6):1628–40.
pubmed: 15124219
Chen Y, Xiao P, Ou-Yang DS, Fan L, Guo D, Wang YN, Han Y, Tu JH, Zhou G, Huang YF, Zhou HH. Simultaneous action of the flavonoid quercetin on cytochrome P450 (CYP) 1A2, CYP2A6, N-acetyltransferase and xanthine oxidase activity in healthy volunteers. Clin Exp Pharmacol Physiol. 2009;36(8):828–33.
pubmed: 19215233
Chen Y, Kang Z, Yan J, et al. Liu wei di huang wan, a well-known traditional Chinese medicine, induces CYP1A2 while suppressing CYP2A6 and N-acetyltransferase 2 activities in man. J Ethnopharmacol. 2010. 28;132(1):213–8.
Chen Y, Liu WH, Chen BL, Fan L, Han Y, Wang G, et al. Plant polyphenol curcumin significantly affects CYP1A2 and CYP2A6 activity in healthy, male Chinese volunteers. Ann Pharmacother. 2010;44(6):1038–45.
pubmed: 20484172
Li YL, Zheng QK. The effect of ofloxacin on pharmacokinetics of theophylline in healthy subjects [in Chinese]. Lin Chuang Yao Xue. 1995;4(4):8–10.
Li Y, Zheng Q, Zhang X, Bi Q, Wu Y, Huang Z. Effect of levofloxacin on pharmacokinetics of theophylline in healthy volunteers and chronic obstructive pulmonary disease patients [in Chinese]. Zhong Guo Lin Chuang Yao Xue Za Zhi. 1999;8(4):217–9.
Qiu F, Wang G, Zhao Y, Sun H, Mao G, Jiyi A, et al. Effect of danshen extract on pharmacokinetics of theophylline in healthy volunteers. Br J Clin Pharmacol. 2008;65(2):270–4.
pubmed: 17961194
Jiang ZR, Weng XY, Zhu YH, Liu MH, Liu CX. Oral pharmacokinetics of theophylline in chronic obstructive pulmonary disease patients older than 60 years [in Chinese]. Tianjin Yao Xue. 1992;4(1):17–20.
Zheng Q, Zhang X, Li Y, Bi Q, Wang D. Effect of ciprofloxacin on theophylline steady-state pharmacokinetics in elderly COPD patients and the observation of clinical adverse-reaction [in Chinese]. Zhong Guo Yi Yuan Yao Xue Za Zhi. 1995;15(10):442–80.
Radke C, Horn D, Lanckohr C, Ellger B, Meyer M, Eissing T, et al. Development of a physiologically based pharmacokinetic modelling approach to predict the pharmacokinetics of vancomycin in critically ill septic patients. Clin Pharmacokinet. 2017;56(7):759–79.
pubmed: 28039606
Kim K, Johnson JA, Derendorf H. Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms. J Clin Pharmacol. 2004;44(10):1083–105.
pubmed: 15342610
Li GF, Gu X, Yu G, Zhao SY, Zheng QS. Comment on: “A physiologically based pharmacokinetic drug-disease model to predict carvedilol exposure in adult and paediatric heart failure patients by incorporating pathophysiological changes in hepatic and renal blood flows”. Clin Pharmacokinet. 2016;55(1):133–7.
pubmed: 26649873
Mukker JK, Singh RS, Derendorf H. Pharmacokinetic and pharmacodynamic considerations in elderly population. In: Stegemann S, editor. Developing drug products in an aging society: from concept to prescribing. New York: Springer; 2014. p. 139–51.
Yu G, Zheng QS, Li GF. Similarities and differences in gastrointestinal physiology between neonates and adults: a physiologically based pharmacokinetic modeling perspective. AAPS J. 2014;16(6):1162–6.
pubmed: 25182208
pmcid: 4389743
De Sousa Mendes M, Lui G, Zheng Y, Pressiat C, Hirt D, Valade E, et al. A Physiologically-based pharmacokinetic model to predict human fetal exposure for a drug metabolized by several CYP450 pathways. Clin Pharmacokinet. 2017;56(5):537–50.
pubmed: 27766562
Dallmann A, Ince I, Solodenko J, Meyer M, Willmann S, Eissing T, et al. Physiologically based pharmacokinetic modeling of renally cleared drugs in pregnant women. Clinical Pharmacokinet. 2017;56(12):1525–41.
Dallmann A, Ince I, Meyer M, Willmann S, Eissing T, Hempel G. Gestation-specific changes in the anatomy and physiology of healthy pregnant women: an extended repository of model parameters for physiologically based pharmacokinetic modeling in pregnancy. Clinical Pharmacokinet. 2017;56(11):1303–30.
Sager JE, Yu J, Raguenau-Majlessi I, Isoherranen N. Physiologically based pharmacokinetic (PBPK) modeling and simulation approaches: a systematic review of published models, applications and model verification. Drug Metab Dispos. 2015;43(11):1823–37.
pubmed: 26296709
pmcid: 4613950
Wagner C, Zhao P, Pan Y, Hsu V, Grillo J, Huang SM, et al. Application of physiologically based pharmacokinetic (PBPK) modeling to support dose selection: report of an FDA public workshop on PBPK. CPT Pharmacometr Syst Pharmacol. 2015;4(4):226–30.
Li GF, Zheng QS. Modeling drug disposition and drug-drug interactions through hypothesis-driven physiologically based pharmacokinetics: a reversal translation perspective. Eur J Drug Metab Pharmacokinet. 2018;43(3):369–71.
pubmed: 29204788